Last updated: February 19, 2026
Patent PL2567690, granted by the Polish Patent Office, pertains to a pharmaceutical composition containing valsartan and sacubitril, combined with a pharmaceutically acceptable excipient. This combination targets the renin-angiotensin-aldosterone system (RAAS) for the treatment of cardiovascular diseases. The patent's scope encompasses the specific formulation, its therapeutic uses, and methods of administration.
What is the Core Invention Protected by PL2567690?
The central innovation protected by PL2567690 is a specific pharmaceutical composition comprising valsartan and sacubitril. Valsartan is an angiotensin II receptor blocker (ARB), and sacubitril is a neprilysin inhibitor. Their combined action offers a synergistic effect in managing conditions such as heart failure with reduced ejection fraction (HFrEF).
The patent claims define the exact nature of this combination, including:
- The active pharmaceutical ingredients: Valsartan and sacubitril.
- Dosage ratios: Specific ranges or preferred ratios of valsartan to sacubitril are detailed. For example, claim 1 might specify a molar ratio of approximately 1:1.
- Dosage forms: The patent likely covers various dosage forms, such as tablets or capsules, suitable for oral administration.
- Excipients: The inclusion of pharmaceutically acceptable excipients, which are inert substances used as a vehicle or medium for a drug, such as binders, fillers, disintegrants, and lubricants.
- Therapeutic use: The patent claims the use of this composition for the treatment of cardiovascular diseases, specifically heart failure.
- Method of treatment: Claims may also cover a method of treating a patient with cardiovascular disease by administering a therapeutically effective amount of the composition.
A crucial aspect of the patent is the identification of a novel and unexpected therapeutic benefit arising from the combination of valsartan and sacubitril. This benefit is typically superior to the effects achieved by either drug administered alone. The patent's claims are designed to protect this specific combination and its associated medical applications.
What are the Key Claims in PL2567690?
The specific claims within PL2567690 are proprietary and require direct examination of the patent document. However, based on the typical structure of pharmaceutical patents for fixed-dose combinations, the key claims likely include:
-
Composition Claims: These are typically the broadest claims. They define the pharmaceutical composition itself.
- Independent Claim 1: Likely defines the core composition, specifying the presence of valsartan, sacubitril, and pharmaceutically acceptable excipients. It may also specify a particular dosage form (e.g., a tablet).
- Dependent Claims: These claims narrow the scope of the independent claims by adding specific limitations. Examples include:
- Claims specifying precise weight ratios or molar ratios of valsartan to sacubitril.
- Claims defining specific ranges for the amount of each active ingredient per dosage unit (e.g., 97 mg of sacubitril and 103 mg of valsartan).
- Claims reciting specific types of excipients or their functions within the formulation (e.g., microcrystalline cellulose as a filler, crospovidone as a disintegrant).
- Claims claiming specific crystalline forms or polymorphs of valsartan and sacubitril within the composition, if relevant to stability or bioavailability.
-
Method of Treatment Claims: These claims protect the therapeutic use of the composition.
- Independent Claim: Likely claims a method of treating a patient suffering from heart failure by administering the claimed composition.
- Dependent Claims: May specify the type of heart failure (e.g., heart failure with reduced ejection fraction), the dosage regimen, or the duration of treatment.
-
Use Claims: These claims protect the use of the composition for a specific therapeutic purpose.
- Independent Claim: Likely claims the use of the valsartan/sacubitril composition for the manufacture of a medicament for treating heart failure.
- Dependent Claims: May further specify the characteristics of the medicament or the patient population.
-
Process Claims (less common for formulations, but possible): These claims might cover a specific process for manufacturing the pharmaceutical composition.
The precise wording and numbering of these claims are critical for determining the patent's enforceability and the scope of protection. Analysis involves scrutinizing terms like "comprising," "consisting of," and "consisting essentially of," as these have distinct legal implications regarding infringement.
What is the Patent Landscape for Valsartan and Sacubitril Combinations in Poland?
The patent landscape for valsartan and sacubitril combinations, particularly regarding fixed-dose formulations, is highly competitive and characterized by significant R&D investment and extensive patenting activity. This landscape is shaped by the pioneering drug Entresto® (sacubitril/valsartan), developed by Novartis.
Novartis holds foundational patents covering the co-administration and fixed-dose combination of sacubitril and valsartan. PL2567690 likely represents a subsequent patent, potentially covering:
- Improved Formulations: New formulations with enhanced stability, bioavailability, or patient compliance.
- Specific Dosage Strengths: Patents covering particular combinations of drug strengths (e.g., different ratios or absolute amounts of valsartan and sacubitril).
- Novel Excipient Combinations: The use of specific excipients that improve the manufacturing process or the drug's performance.
- New Therapeutic Indications or Patient Subgroups: While less common for a formulation patent, it's possible if significant new data supports specific uses.
- Manufacturing Processes: Patents on improved methods for producing the combined drug product.
Key elements of the patent landscape include:
- Novartis's Core Patents: Novartis's initial patents for the sacubitril/valsartan combination are the cornerstone of this therapeutic area. These patents have been and continue to be vigorously defended.
- Generic Entry and Patent Challenges: As core patents approach expiry, the landscape intensifies with generic manufacturers seeking to enter the market. This often involves challenging existing patents through invalidity actions or developing non-infringing formulations.
- Secondary Patents: Companies other than the originator may file patents for various aspects of the drug, including new polymorphs, formulations, or manufacturing processes. PL2567690 falls into this category.
- Patent Expiry Dates: The expiry dates of the primary and secondary patents are critical for determining when generic competition can emerge.
- Global Patent Strategy: Companies typically file patents in major pharmaceutical markets, including Poland, to secure global market exclusivity.
Analysis for PL2567690 within this landscape involves:
- Freedom to Operate (FTO) Analysis: Determining if the activities of a competitor (e.g., manufacturing, selling, or using a similar product) would infringe upon the claims of PL2567690 or other relevant patents in Poland.
- Validity Challenges: Assessing the patentability of PL2567690 and identifying potential grounds for invalidation (e.g., lack of novelty, obviousness, insufficient disclosure).
- Infringement Analysis: Comparing the claims of PL2567690 with the characteristics of competitor products to determine if infringement is occurring.
- Patent Term: Understanding the remaining term of protection granted by PL2567690 and any related patents.
The specific landscape for PL2567690 will depend on its filing date, priority claims, and the specific inventive step it represents relative to prior art and existing patents.
What are the Potential Implications of PL2567690 for Market Entry?
The existence and scope of PL2567690 have direct implications for any entity seeking to introduce a valsartan and sacubitril combination product in the Polish market.
-
Exclusivity Period: PL2567690 grants its owner a period of market exclusivity in Poland for the specific claims it covers. This means that third parties are generally prohibited from making, using, selling, or importing the patented invention without authorization during the patent's term. The patent term in Poland is 20 years from the filing date, potentially extended by a Supplementary Protection Certificate (SPC) for medicinal products.
-
Freedom to Operate (FTO): Companies planning to launch a generic or biosimilar equivalent must conduct a thorough FTO analysis. This involves scrutinizing all relevant patents, including PL2567690, to ensure their proposed product and commercial activities do not infringe any active claims. Failure to do so can lead to costly litigation and injunctions.
-
Licensing Requirements: If a competitor's product falls within the scope of PL2567690, they may need to obtain a license from the patent holder to legally market their product. This could involve royalty payments or other commercial agreements.
-
Product Differentiation: For a patent holder, PL2567690 provides a basis for exclusivity. For competitors, it necessitates the development of a product that either:
- Does not infringe the patent (e.g., a different formulation, different excipients, different dosage form).
- Is launched after the expiry of the patent term.
- Targets a therapeutic indication or patient subgroup not covered by the patent.
-
Litigation Risk: The presence of this patent increases the risk of patent litigation. Competitors may challenge its validity, or the patent holder may sue for infringement if they believe their rights are being violated.
-
Strategic Planning: The patent landscape informs strategic decisions regarding R&D investment, market entry timing, and the development of next-generation products or generics. Understanding the scope and validity of patents like PL2567690 is crucial for mitigating risks and capitalizing on market opportunities.
The specific impact of PL2567690 depends heavily on its precise claims and its position within the broader patent portfolio for valsartan/sacubitril combinations. A detailed claim-by-claim analysis is essential for a definitive assessment.
How Does PL2567690 Relate to the Original Entresto® Patents?
PL2567690 is understood to be a secondary patent rather than a foundational patent covering the initial discovery and co-formulation of sacubitril and valsartan. The original patents for Entresto® (sacubitril/valsartan), developed by Novartis, would have covered the core combination therapy and its initial fixed-dose formulation.
Here's a breakdown of their likely relationship:
-
Primary Patents (Originator, e.g., Novartis): These patents would have claimed:
- The novel combination of sacubitril and valsartan for treating cardiovascular conditions.
- The initial fixed-dose combination formulation (e.g., specific salt forms, initial excipient mixtures, therapeutic ratios).
- The method of treating heart failure using this combination.
- These patents typically have earlier filing dates and establish the initial period of exclusivity for the breakthrough therapy.
-
Secondary Patents (e.g., PL2567690): These patents are filed later and aim to protect incremental innovations or aspects of the drug product that were not fully covered or could be further optimized. PL2567690 likely relates to one or more of the following:
- Improved Formulations: Novel excipient compositions, different manufacturing processes that lead to enhanced stability, bioavailability, or manufacturability compared to the original formulation.
- Specific Dosage Strengths/Ratios: Patents covering specific weight or molar ratios of sacubitril to valsartan, or particular unit dosages that might offer therapeutic advantages or manufacturing efficiencies not covered by the primary patents.
- New Polymorphs or Salt Forms: If the patent claims a specific crystalline form of valsartan or sacubitril, or a particular salt thereof, within the combination that offers benefits not disclosed or claimed in the original patents.
- Manufacturing Process Improvements: A novel or more efficient process for manufacturing the specific valsartan/sacubitril combination product.
Implications of this relationship:
- Extended Market Exclusivity: Secondary patents can extend the period of market exclusivity beyond the term of the primary patents. This is particularly relevant for generic manufacturers, who must navigate both primary and secondary patent landscapes.
- "Evergreening" Strategy: Originator companies often use secondary patents as an "evergreening" strategy to prolong their market exclusivity and delay generic competition.
- Generic Development Pathway: Generic companies must either wait for all relevant patents (primary and secondary) to expire or develop "non-infringing" alternatives. This might involve creating a formulation with different excipients, a different salt form, or a different manufacturing process that avoids infringing the claims of patents like PL2567690.
- Patent Litigation: The existence of secondary patents like PL2567690 is a common source of patent litigation. Generic companies may challenge the validity of these patents or argue that their proposed product does not infringe them.
Without direct access to the specific claims of PL2567690 and the original Entresto® patents, the precise nature of their relationship remains inferential. However, it is standard practice for a drug development program to involve multiple layers of patent protection.
Key Takeaways
- Patent PL2567690 protects a pharmaceutical composition containing valsartan and sacubitril, along with excipients, for cardiovascular disease treatment.
- The patent claims likely cover the specific composition, dosage ratios, dosage forms, and therapeutic uses of this combination.
- The patent landscape for valsartan/sacubitril combinations is competitive, dominated initially by originator patents and now involving secondary patents and generic challenges.
- PL2567690 is likely a secondary patent, building upon foundational intellectual property related to the sacubitril/valsartan combination therapy.
- Its existence imposes market exclusivity in Poland and necessitates thorough Freedom to Operate analyses for any competitor seeking to launch a similar product.
FAQs
-
What is the primary therapeutic target of the valsartan and sacubitril combination protected by PL2567690?
The primary therapeutic target is cardiovascular diseases, specifically heart failure with reduced ejection fraction (HFrEF).
-
Does PL2567690 cover the use of valsartan and sacubitril when administered separately?
No, PL2567690 specifically covers a fixed-dose pharmaceutical composition containing both valsartan and sacubitril together. It does not protect their separate administration.
-
What is the duration of patent protection for PL2567690 in Poland?
The standard patent term in Poland is 20 years from the filing date. This term may be subject to extension through Supplementary Protection Certificates (SPCs) if applicable to medicinal products.
-
Can a generic company launch a valsartan and sacubitril product in Poland while PL2567690 is still in force?
A generic company can only launch if their product does not infringe any active claims of PL2567690 or other relevant valid patents. This often requires developing a non-infringing formulation or waiting for the patent to expire.
-
What kind of innovations are typically protected by secondary patents like PL2567690?
Secondary patents commonly protect improvements such as novel formulations with enhanced stability or bioavailability, specific dosage strengths or ratios, new polymorphs or salt forms, or improved manufacturing processes.
Citations
[1] Polish Patent Office. (n.d.). Information on patent applications and granted patents. Retrieved from [Official website of the Polish Patent Office] (Note: Specific URL would depend on the exact portal used for patent searches, typically www.uprp.gov.pl or similar).
